phase 2
ii 1
intergroup 1
trial 2
alisertib 1
relapsed 1
refractory 1
peripheral 1
tcell 1
lymphoma 2
transformed 1
mycosis 1
fungoides 1
swog 1
comparative 1
analysis 1
prognostic 1
factor 1
models 1
follicular 1
based 1
iii 1
choprituximab 1
versus 1
chop 1
iodinetositumomab 1
